MagnetisMM-5: Study of Elranatamab (PF-06863135) Monotherapy and Elranatamab + Daratumumab Versus Daratumumab + Pomalidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
- Conditions
- Multiple Myeloma
- Interventions
- Registration Number
- NCT05020236
- Lead Sponsor
- Pfizer
- Brief Summary
The purpose of this study is to evaluate whether the BCMA-CD3 bispecific antibody elranatamab, alone and/or in combination with the anti-CD38 monoclonal antibody, daratumumab, can provide more benefit to people with multiple myeloma compared to a combination therapy including daratumumab, pomalidomide, and dexamethasone. People with multiple myeloma who have received previous treatment including lenalidomide and a proteasome inhibitor will be enrolled in the study. Part 1 of the study will assess the safety and activity of different doses of elranatamab in combination with daratumumab. People participating in Part 2 of the study will be randomly assigned to receive either elranatamab alone, elranatamab plus daratumumab, or daratumumab, pomalidomide, and dexamethasone. Part 2 will compare the safety and activity of (1) elranatamab alone compared to daratumumab, pomalidomide, and dexamethasone, and (2) elranatamab plus daratumumab compared to daratumumab, pomalidomide, and dexamethasone. Participants in all parts of the study will receive study treatment until their disease progresses, they experience unacceptable side effects, or they choose to no longer participate in the study.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ACTIVE_NOT_RECRUITING
- Sex
- All
- Target Recruitment
- 759
-
Prior diagnosis of multiple myeloma as defined by IMWG criteria (Rajkumar et al, 2014).
-
Measurable disease based on IMWG criteria as defined by at least 1 of the following:
- Serum M-protein ≥0.5 g/dL.
- Urinary M-protein excretion ≥200 mg/24 hours.
- Serum immunoglobulin FLC ≥10 mg/dL (≥100 mg/L) AND abnormal serum immunoglobulin kappa to lambda FLC ratio (<0.26 or >1.65).
-
Prior anti-multiple myeloma therapy including treatment with lenalidomide and a proteasome inhibitor.
-
ECOG performance status ≤2.
-
Resolved acute effects of any prior therapy to baseline severity or CTCAE Grade ≤1.
-
Not pregnant and willing to use contraception.
- Smoldering multiple myeloma.
- Plasma cell leukemia.
- Amyloidosis.
- POEMS Syndrome.
- Stem cell transplant within 12 weeks prior to enrolment, or active graft versus host disease.
- Active HBV, HCV, SARS-CoV2, HIV, or any active, uncontrolled bacterial, fungal, or viral infection.
- Any other active malignancy within 3 years prior to enrolment, except for adequately treated basal cell or squamous cell skin cancer, or carcinoma in situ.
- Previous treatment with a BCMA-directed therapy.
- Anti-CD38-directed therapy within 6 months preceding the first dose of treatment in this study.
- Live attenuated vaccine within 4 weeks of the first dose of study intervention.
- Administration with an investigational product (e.g. drug or vaccine) concurrent with study intervention or within 30 days preceding the first dose of study intervention used in this study.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- FACTORIAL
- Arm && Interventions
Group Intervention Description Part 2 Randomized Arm C: Daratumumab + Pomalidomide + Dexamethasone Pomalidomide - Part 2 Randomized Arm B: Elranatamab + Daratumumab Daratumumab - Part 1 Safety Lead-In Dose Escalation: Elranatamab + Daratumumab Elranatamab - Part 2 Randomized Arm C: Daratumumab + Pomalidomide + Dexamethasone Dexamethasone - Part 2 Randomized Arm A: Elranatamab Elranatamab - Part 2 Randomized Arm B: Elranatamab + Daratumumab Elranatamab - Part 1 Safety Lead-In Dose Escalation: Elranatamab + Daratumumab Daratumumab - Part 2 Randomized Arm C: Daratumumab + Pomalidomide + Dexamethasone Daratumumab -
- Primary Outcome Measures
Name Time Method Part 2 Randomized: Progression free survival per International Myeloma Working Group criteria From date of randomization to date of progressive disease, discontinuation from the study, death, or censoring, whichever occurs first, assessed up to 51 months Part 1 Safety Lead-In: Incidence of dose limiting toxicities First 42 days after first elranatamab dose
- Secondary Outcome Measures
Name Time Method Overall survival From date of randomization to date of discontinuation from study, death, or censoring, whichever occurs first, assessed up to 51 months Time to response per International Myeloma Working Group criteria From date of randomization to date of confirmed objective response, assessed up to 51 months Progression free survival on next-line treatment per International Myeloma Working Group criteria From date of randomization to date of second objective disease progression, discontinuation from the study, death, or censoring, whichever occurs first, assessed up to 51 months Frequency of treatment-emergent adverse events From date of first dose of study intervention through minimum of 90 days after last study intervention administration. Reporting of non-serious AEs ends at start of new anti-cancer therapy. Frequency of abnormal laboratory results From date of first dose of study intervention through minimum of 90 days after last study intervention administration. Reporting of non-serious AEs ends at start of new anti-cancer therapy. Daratumumab pharmacokinetics by pre-dose concentrations From date of first dose through up to 14 days after date of last dose of daratumumab Part 1 Safety Lead-In: Progression free survival per International Myeloma Working Group criteria From date of randomization to date of progressive disease, discontinuation from study, death, or censoring, whichever occurs first, assessed up to 51 months Objective response rate per International Myeloma Working Group criteria From date of randomization to date of progressive disease, discontinuation from study, death, or start of new anticancer therapy, whichever occurs first, assessed up to 51 months Complete response rate per International Myeloma Working Group criteria From date of randomization to date of progressive disease, discontinuation from study, death, or start of new anticancer therapy, whichever occurs first, assessed up to 51 months Minimal residual disease negativity rate per International Myeloma Working Group criteria From date of randomization to date of progressive disease, discontinuation from study, death, or start of new anticancer therapy, whichever occurs first, assessed up to 51 months Rate of Grade ≥2 cytokine release syndrome First 28 days after first elranatamab dose Elranatamab immunogenicity by anti-drug antibodies against elranatamab From date of first dose through up to 14 days after date of last dose of elranatamab Health-related quality of life by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire - Myeloma 20 From date of informed consent through up to 35 days after date of last dose of study intervention Duration of response per International Myeloma Working Group criteria From date of confirmed objective response to date of progressive disease, discontinuation from study, death, or censoring, whichever occurs first, assessed up to 51 months Duration of complete response per International Myeloma Working Group criteria From date of confirmed complete response to date of progressive disease, discontinuation from study, death, or censoring, whichever occurs first, assessed up to 51 months Sustained minimal residual disease negativity rate per International Myeloma Working Group criteria From date of randomization to date of progressive disease, discontinuation from study, death, or start of new anticancer therapy, whichever occurs first, assessed up to 51 months Elranatamab pharmacokinetics by pre- and post-dose concentrations From date of first dose through up to 14 days after date of last dose of elranatamab Health-related quality of life by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire - Core 30 From date of informed consent through up to 35 days after date of last dose of study intervention
Trial Locations
- Locations (239)
Harbin Medical University Cancer Hospital
🇨🇳Harbin, Heilongjiang, China
Helsinki University Hospital - Comprehensive Cancer Center (HYKS - Syöpäkeskus)
🇫🇮Helsinki, Finland
Centre Hospitalier Universitaire de Limoges - Hôpital Dupuytren
🇫🇷Limoges, Limousin, France
Hopital Claude Huriez - CHU de Lille
🇫🇷Lille, Nord, France
Centre Hospitalier Universitaire de Nantes - L' Hopital l'hôtel-Dieu
🇫🇷Nantes Cedex 1, France
National Hospital Organization Kumamoto Medical Center
🇯🇵Kumamoto, Japan
Nagasaki University Hospital
🇯🇵Nagasaki, Japan
National Hospital Organization Okayama Medical Center
🇯🇵Okayama, Japan
Capital, Coast and Hutt Valley District - Wellington Regional Hospital
🇳🇿Wellington, New Zealand
Pharmacy on Shakespeare
🇳🇿Takapuna, New Zealand
Haukeland Universitetssjukehus
🇳🇴Bergen, Hordaland, Norway
Stavanger Universitetssykehus
🇳🇴Stavanger, Rogaland, Norway
Oslo Universitetssykehus Ullevål
🇳🇴Oslo, Norway
St Olavs Hospital
🇳🇴Trondheim, Norway
Szpital Uniwersytecki nr 2 im. dr Jana Biziela w Bydgoszczy Klinika Hematologii
🇵🇱Bydgoszcz, Poland
Uniwersyteckie Centrum Kliniczne
🇵🇱Gdansk, Poland
Pratia Onkologia Katowice
🇵🇱Katowice, Poland
Inonu Universitesi Turgut Ozal Tıp Merkezi
🇹🇷Malatya, Turkey
Clovis Community Medical Center
🇺🇸Clovis, California, United States
Community Cancer Institute
🇺🇸Clovis, California, United States
University of California San Francisco
🇺🇸Fresno, California, United States
Community Regional Medical Center
🇺🇸Fresno, California, United States
UCHealth Poudre Valley Hospital
🇺🇸Fort Collins, Colorado, United States
UCHealth Harmony
🇺🇸Fort Collins, Colorado, United States
UCHealth Greeley Hospital
🇺🇸Greeley, Colorado, United States
UCHealth - Medical Center of the Rockies
🇺🇸Loveland, Colorado, United States
Sylvester Comprehensive Cancer Center - Aventura
🇺🇸Aventura, Florida, United States
Sylvester Comprehensive Cancer Center- The Lennar Foundation Medical Center
🇺🇸Coral Gables, Florida, United States
Sylvester Comprehensive Cancer Center - Coral Springs
🇺🇸Coral Springs, Florida, United States
University of Miami Hospital and Clinics - Deerfield Beach
🇺🇸Deerfield Beach, Florida, United States
Sylvester Comprehensive Cancer Center - Hollywood
🇺🇸Hollywood, Florida, United States
Sylvester Comprehensive Cancer Center
🇺🇸Miami, Florida, United States
University of Miami Hospital And Clinics
🇺🇸Miami, Florida, United States
Sylvester Comprehensive Cancer Center - Kendall
🇺🇸Miami, Florida, United States
Sylvester Comprehensive Cancer Center - Plantation
🇺🇸Plantation, Florida, United States
East Jefferson General Hospital Bone Marrow Transplant Clinic
🇺🇸Metairie, Louisiana, United States
East Jefferson General Hospital
🇺🇸Metairie, Louisiana, United States
MSK Basking Ridge
🇺🇸Basking Ridge, New Jersey, United States
MSK Monmouth
🇺🇸Middletown, New Jersey, United States
MSK Bergen
🇺🇸Montvale, New Jersey, United States
MSK Commack
🇺🇸Commack, New York, United States
MSK Westchester
🇺🇸Harrison, New York, United States
Memorial Sloan Kettering Cancer Center - David H. Koch Center for Cancer Care (74th Street).
🇺🇸New York, New York, United States
Memorial Sloan Kettering Cancer Center - Main Campus
🇺🇸New York, New York, United States
MSK Nassau
🇺🇸Uniondale, New York, United States
Alexander Fleming S.A (Instituto Medico Especializado Alexander Fleming)
🇦🇷Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina
FUNDALEU - Fundacion para combatir la Leucemia
🇦🇷Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina
FUNDALEU -Fundación para combatir la leucemia
🇦🇷Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina
FUNDALEU
🇦🇷Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina
Hospital Universitario Austral
🇦🇷Derqui, Buenos Aires, Argentina
Hospital Italiano de La Plata
🇦🇷La Plata, Buenos Aires, Argentina
Sanatorio de La Mujer
🇦🇷Rosario, Santa FE, Argentina
Pindara Private Hospital
🇦🇺Benowa, Queensland, Australia
QScan Radiology Clinics
🇦🇺Clayfield, Queensland, Australia
Gallipoli Medical Research Foundation
🇦🇺Greenslopes, Queensland, Australia
Greenslopes Private Hospital
🇦🇺Greenslopes, Queensland, Australia
Princess Alexandra Hospital
🇦🇺Woolloongabba, Queensland, Australia
Epworth Freemasons
🇦🇺East Melbourne, Victoria, Australia
St Vincent's Hospital (Melbourne)
🇦🇺Fitzroy, Victoria, Australia
Barwon Health
🇦🇺Geelong, Victoria, Australia
The Alfred Hospital
🇦🇺Melbourne, Victoria, Australia
Epworth Healthcare
🇦🇺Richmond, Victoria, Australia
Slade Pharmacy
🇦🇺Richmond, Victoria, Australia
Linear Clinical Research
🇦🇺Perth, Western Australia, Australia
Universitätsklinikum Krems
🇦🇹Krems, Niederösterreich, Austria
Klinik Ottakring
🇦🇹Vienna, Wien, Austria
Universitätsklinik für Innere Medizin V Innsbruck
🇦🇹Innsbruck, Austria
Uniklinikum Salzburg
🇦🇹Salzburg, Austria
Medizinische Universität Wien
🇦🇹Wien, Austria
Grand Hôpital de Charleroi
🇧🇪Gilly, Hainaut, Belgium
CHU UCL Namur (site Godinne)
🇧🇪Yvoir, Namur, Belgium
Université Catholique de Louvain-Namur - Centre Hospitalier Universitaire Dinant-Godinne - Site Godi
🇧🇪Yvoir, Namur, Belgium
Instituto D'Or de Pesquisa e Ensino (IDOR) - Filial Salvador
🇧🇷Salvador, Bahia, Brazil
Centro Gaucho Integrado De Oncologia, Hematologia, Ensino E Pesquisa
🇧🇷Porto Alegre, RIO Grande DO SUL, Brazil
Centro de Pesquisa Clínica - Área Administrativa
🇧🇷Porto Alegre, RIO Grande DO SUL, Brazil
Hospital Mae de Deus
🇧🇷Porto Alegre, RIO Grande DO SUL, Brazil
BP - A Beneficencia Portuguesa de São Paulo
🇧🇷Sao Paulo, SÃO Paulo, Brazil
Clínica Médica São Germano LTDA
🇧🇷SP, SÃO Paulo, Brazil
Hospital Américas Medical City
🇧🇷Rio de Janeiro, Brazil
Instituto de Educação, Pesquisa e Gestão em Saúde
🇧🇷Rio de Janeiro, Brazil
ESHO Empresa de Serviços Hospitalares S.A/ Hospital Samaritano de Higienópolis
🇧🇷São Paulo, Brazil
IDOR Ensino e Pesquisa
🇧🇷São Paulo, Brazil
HU UNIFESP / SPDM - Hospital São Paulo
🇧🇷São Paulo, Brazil
Universidade Federal de Sao Paulo
🇧🇷São Paulo, Brazil
Clínica Médica São Germano S/S Ltda
🇧🇷São Paulo, Brazil
Instituto D'Or de Pesquisa e Ensino (IDOR)
🇧🇷São Paulo, Brazil
Arthur J.E. Child Comprehensive Cancer Centre
🇨🇦Calgary, Alberta, Canada
Cross Cancer Institute
🇨🇦Edmonton, Alberta, Canada
Hamilton Health Sciences-Juravinski Cancer Centre
🇨🇦Hamilton, Ontario, Canada
Shenzhen Second People's Hospital
🇨🇳Shenzhen, Guangdong, China
QEII Health Sciences Centre - Victoria General Site
🇨🇦Halifax, Nova Scotia, Canada
Princess Margaret Cancer Centre
🇨🇦Toronto, Ontario, Canada
Jewish General Hospital
🇨🇦Montreal, Quebec, Canada
CIUSSS de l'Est-de-l'Île-de-Montréal
🇨🇦Montréal, Quebec, Canada
Saskatoon Cancer Center
🇨🇦Saskatoon, Saskatchewan, Canada
Peking University Third Hospital
🇨🇳Beijing, Beijing, China
Beijing Peking Union Medical College Hospital
🇨🇳Beijing, Beijing, China
Fujian Medical University Union Hospital
🇨🇳Fuzhou, Fujian, China
Guangdong Provincial People's Hospital
🇨🇳Guangzhou, Guangdong, China
Nanfang Hospital of Southern Medical University
🇨🇳Guangzhou, Guangdong, China
The Second Hospital of Hebei Medical University
🇨🇳Shijiazhuang, Hebei, China
Henan Cancer Hospital
🇨🇳Zhengzhou, Henan, China
Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology
🇨🇳Wuhan, Hubei, China
The Affiliated Hospital of Xuzhou Medical University
🇨🇳Xuzhou, Jiangsu, China
Sun Yat-sen University Cancer Center
🇨🇳Guangzhou, Guangdong, China
Nanjing Drum Tower Hospital ， The Affiliated Hospital of Nanjing University Medical School
🇨🇳Nanjing, Jiangsu, China
The First Affiliated Hospital of Nanchang University
🇨🇳Nanchang, Jiangxi, China
Shandong Provincial Hospital
🇨🇳Jinan, Shandong, China
Jinan Central Hospital
🇨🇳Jinan, Shandong, China
Tianjin Medical University General Hospital
🇨🇳Tianjin, Tianjin, China
Jilin Province Cancer Hospital
🇨🇳Changchun, Jilin, China
The First Hospital of Jilin University
🇨🇳Changchun, Jilin, China
Institute of hematology&blood disease hospital
🇨🇳Tianjin, Tianjin, China
The First Affiliated Hospital, Zhejiang University
🇨🇳Hangzhou, Zhejiang, China
The First Affiliated Hospital of Wenzhou Medical University
🇨🇳Wenzhou, Zhejiang, China
Beijing Boren Hospital
🇨🇳Beijing, China
Chongqing University Cancer Hospital
🇨🇳Chongqing, China
Fakultní nemocnice Brno Bohunice
🇨🇿Brno, Brno-m?sto, Czechia
Fakultni Nemocnice Plzen
🇨🇿Plzen - Lochotin, Plzeňský KRAJ, Czechia
Fakultni poliklinika
🇨🇿Praha, Praha 2, Czechia
Fakultni nemocnice Hradec Kralove
🇨🇿Hradec Kralove, Czechia
Fakultni nemocnice Olomouc
🇨🇿Olomouc, Czechia
Fakultni nemocnice Ostrava
🇨🇿Ostrava-Poruba, Czechia
Vseobecna fakultni nemocnice v Praze
🇨🇿Praha 2, Czechia
Tampereen yliopistollinen sairaala
🇫🇮Tampere, Finland
Oulun yliopistollinen sairaala
🇫🇮Oulu, Pohjois-pohjanmaa, Finland
Kuopion Yliopistollinen Sairaala
🇫🇮Kuopio, Pohjois-savo, Finland
Turku University Hospital
🇫🇮Turku, Varsinais-suomi, Finland
Hôpital Saint Antoine
🇫🇷Paris Cedex 12, France
Hopital Necker
🇫🇷Paris, France
Centre Hospitalier Lyon Sud - Service d'Hematologie Clinique
🇫🇷Pierre Benite Cedex, France
CHU de Poitiers, Hôpital de la Milétrie, Pôle Régional de Cancérologie
🇫🇷Poitiers Cedex, France
Institut Universitaire du Cancer Toulouse - Oncopole - CHU de TOULOUSE
🇫🇷Toulouse, France
Universitaetsklinikum Ulm
🇩🇪Ulm, Baden-württemberg, Germany
Universitätsklinikum Würzburg
🇩🇪Würzburg, Bayern, Germany
Charité Universitätsmedizin Berlin
🇩🇪Berlin, Germany
Staedtisches Klinikum Braunschweig gGmbH
🇩🇪Braunschweig, Germany
Klinikum Chemnitz gGMbH
🇩🇪Chemnitz, Germany
Universitätsklinikum rechts der Isar, Technische Universität München (TUM)
🇩🇪Muenchen, Germany
Evangelismos General Hospital of Athens
🇬🇷Athens, Attikí, Greece
Alexandra General Hospital of Athens
🇬🇷Athens, Attikí, Greece
Radiology vendor
🇬🇷Athina, Attikí, Greece
Theageneio Cancer Hospital of Thessaloniki
🇬🇷Thessaloniki, Kentrikí Makedonía, Greece
University General Hospital of Ioannina
🇬🇷Ioannina, Greece
IRCCS - Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori"
🇮🇹Meldola, Emilia-romagna, Italy
Ospedale San Martino
🇮🇹Genova, Liguria, Italy
Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico
🇮🇹Milano, Lombardia, Italy
Fondazione IRCCS San Gerardo dei Tintori
🇮🇹Monza, Lombardia, Italy
ASST Santi Paolo e Carlo Ospedale San Carlo Borromeo SSD di Onco-Ematologia (Edificio C-piano terra)
🇮🇹Milano, Milan, Italy
Policlinico "G. Rodolico"
🇮🇹Catania, Sicilia, Italy
IRCCS Azienda Ospedaliero-Universitaria di Bologna, Policlinico di Sant'Orsola
🇮🇹Bologna, Italy
AOU Policlinico Umberto I
🇮🇹Roma, Italy
Fondazione Policlinico Universitario Agostino Gemelli
🇮🇹Roma, Italy
Nagoya City University Hospital
🇯🇵Nagoya, Aichi, Japan
University of Fukui Hospital
🇯🇵Yoshida-gun, Fukui, Japan
National Hospital Organization Shibukawa Medical Center
🇯🇵Shibukawa, Gunma, Japan
Iwate Medical University Hospital
🇯🇵Yahaba-cho, Iwate, Japan
Tohoku University Hospital
🇯🇵Sendai, Miyagi, Japan
Shizuoka Cancer Center
🇯🇵Sunto-gun, Shizuoka, Japan
Japanese Red Cross Medical Center
🇯🇵Shibuya-ku, Tokyo, Japan
Akita University Hospital
🇯🇵Akita, Japan
National Hospital Organization Kyushu Cancer Center
🇯🇵Fukuoka, Japan
Kagoshima University Hospital
🇯🇵Kagoshima, Japan
Osaka Metropolitan University Hospital
🇯🇵Osaka, Japan
Tokushima University Hospital
🇯🇵Tokushima, Japan
Yamagata University Hospital
🇯🇵Yamagata, Japan
Seoul National University Bundang Hospital
🇰🇷Seongnam-si, Gyeonggi-do, Korea, Republic of
Chonnam National University Hwasun Hospital
🇰🇷Hwasun-gun, Jeonranamdo, Korea, Republic of
Pusan National University Hospital
🇰🇷Busan, Pusan-kwangyǒkshi, Korea, Republic of
Seoul National University Hospital
🇰🇷Seoul, Seoul-teukbyeolsi [seoul], Korea, Republic of
Samsung Medical Center
🇰🇷Seoul, Seoul-teukbyeolsi [seoul], Korea, Republic of
The Catholic Univ. of Korea Seoul St. Mary's Hospital
🇰🇷Seoul, Seoul-teukbyeolsi [seoul], Korea, Republic of
Kyungpook National University Hospital
🇰🇷Daegu, Taegu-kwangyǒkshi, Korea, Republic of
Gachon University Gil Medical Center
🇰🇷Incheon, Korea, Republic of
Asan Medical Center
🇰🇷Seoul, Korea, Republic of
Hematológica Alta Especialidad SC, consultorio 830
🇲🇽Colonia Valle De Las Palmas, México, Mexico
Hospital Universitario "Dr. Jose Eleuterio Gonzalez"
🇲🇽Monterrey, Nuevo LEÓN, Mexico
Centro de Investigacion Clinica de Oaxaca
🇲🇽Oaxaca, Mexico
Instituto Veracruzano en Investigación Clínica S.C.
🇲🇽Veracruz, Mexico
Erasmus Universitair Medisch Centrum
🇳🇱Rotterdam, Zuid-holland, Netherlands
Maastricht University Medical Center
🇳🇱Maastricht, Netherlands
North Shore Hospital
🇳🇿Auckland, New Zealand
Labtests Auckland Ltd.
🇳🇿Auckland, New Zealand
Aotearoa Clinical Trials
🇳🇿Auckland, New Zealand
Waikato District Health Board, Waikato Hospital
🇳🇿Hamilton, New Zealand
TRG Imaging
🇳🇿Milford, New Zealand
Pacific Radiology
🇳🇿Newtown, New Zealand
Broadway Radiology
🇳🇿Palmerston North, New Zealand
Palmerston North Hospital
🇳🇿Roslyn, New Zealand
Uniwersytecki Szpital Kliniczny w Poznaniu
🇵🇱Poznan, Poland
Centrum Medyczne Pratia Poznan
🇵🇱Skorzewo, Poland
Uniwersyteckie Centrum Kliniczne WUM Centralny Szpital Kliniczny
🇵🇱Warszawa, Poland
Uniwersytecki Szpital Kliniczny im. Jana Mikulicza-Radeckiego we Wroclawiu
🇵🇱Wroclaw, Poland
Complejo Hospitalario Universitario de Santiago
🇪🇸Santiago de Compostela, A Coruna, Spain
Institut Català d'Oncologia - L'Hospitalet
🇪🇸L'Hospitalet Del Llobregat, Barcelona [barcelona], Spain
Hospital Universitari Mutua Terrassa
🇪🇸Terrassa, Barcelona, Spain
Hospital Universitario Marqués de Valdecilla
🇪🇸Santander, Cantabria, Spain
Clinica Universidad de Navarra
🇪🇸Pamplona, Navarra, Spain
Hospital Universitario de Toledo
🇪🇸Toledo, Other, Spain
Hospital Universitari Vall d'Hebron
🇪🇸Barcelona, Spain
Hospital Clinic Barcelona
🇪🇸Barcelona, Spain
Hospital Universitari De Girona Doctor Josep Trueta
🇪🇸Girona, Spain
Hospital Universitario La Princesa
🇪🇸Madrid, Spain
Hospital Universitario Madrid Sanchinarro
🇪🇸Madrid, Spain
Hospital Universitario de Salamanca
🇪🇸Salamanca, Spain
Hospital Universitario Virgen Del Rocio
🇪🇸Sevilla, Spain
Hospital Universitario y Politecnico La Fe
🇪🇸Valencia, Spain
Skånes Universitetssjukhus Lund
🇸🇪Lund, Skåne LÄN [se-12], Sweden
Södra Älvsborg Sjukhus
🇸🇪Borås, Sweden
Falu Lasarett
🇸🇪Falun, Sweden
Sahlgrenska Universitetssjukhuset
🇸🇪Göteborg, Sweden
Sunderby Sjukhus
🇸🇪Luleå, Sweden
Universitetssjukhuset Örebro
🇸🇪Örebro, Örebro LÄN [se-18], Sweden
Läkemedelsberedningen
🇸🇪Linköping, Östergötlands LÄN [se-05], Sweden
Universitetssjukhuset i Linköping
🇸🇪Linköping, Östergötlands LÄN [se-05], Sweden
Chang Gung Memorial Hospital at Kaohsiung
🇨🇳Kaohsiung, Taiwan
China Medical University Hospital
🇨🇳Taichung, Taiwan
National Cheng Kung University Hospital
🇨🇳Tainan, Taiwan
National Taiwan University Hospital
🇨🇳Taipei, Taiwan
Taipei Veterans General Hospital
🇨🇳Taipei, Taiwan
Istanbul Universitesi Istanbul Tıp Fakultesi Hastanesi
🇹🇷Istanbul, İ̇stanbul, Turkey
Medipol Mega Universite Hastanesi
🇹🇷İstanbul, İ̇stanbul, Turkey
Acibadem Universitesi Atakent Hastanesi
🇹🇷Istanbul, İ̇stanbul, Turkey
Sisli Florence Nightingale Hastanesi
🇹🇷İstanbul, İ̇stanbul, Turkey
Ege Universitesi Hastanesi
🇹🇷İzmir, İ̇zmir, Turkey
Dokuz Eylul Universitesi Hastanesi
🇹🇷İzmir, İ̇zmir, Turkey
Baskent Universitesi Adana Dr. Turgut Noyan Uygulama ve Arastirma Merkezi
🇹🇷Adana, Turkey
Ankara University Health Practice and Research Hospitals
🇹🇷Ankara, Turkey
Dr. Abdurrahman Yurtaslan Ankara Onkoloji Egitim ve Arastırma Hastanesi
🇹🇷Ankara, Turkey
Akdeniz Universitesi Hastanesi
🇹🇷Antalya, Turkey
Gaziantep Universitesi Sahinbey Arastirma ve Uygulama Hastanesi
🇹🇷Gaziantep, Turkey
Erciyes Universitesi Tıp Fakultesi Hastaneleri
🇹🇷Kayseri, Turkey
Özel Anadolu Sağlık Merkezi
🇹🇷Kocaeli, Turkey
Royal Bournemouth Hospital
🇬🇧Bournemouth, Dorset, United Kingdom
Churchill Hospital, Oxford University Hospitals NHS Foundation Trust
🇬🇧Oxford, Oxfordshire, United Kingdom
University Hospital of Wales
🇬🇧Cardiff, South Glamorgan, United Kingdom
Bristol Haematology and Oncology Centre
🇬🇧Bristol, United Kingdom
Kent and Canterbury Hospital
🇬🇧Canterbury, United Kingdom
The Christie NHS Foundation Trust
🇬🇧Manchester, United Kingdom